These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 28044946)

  • 1. Optimizing outcomes in ADHD treatment: from clinical targets to novel delivery systems.
    Mattingly GW; Anderson RH
    CNS Spectr; 2016 Dec; 21(S1):45-59. PubMed ID: 28044946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders.
    Osland ST; Steeves TD; Pringsheim T
    Cochrane Database Syst Rev; 2018 Jun; 6(6):CD007990. PubMed ID: 29944175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances in the treatment of attention-deficit/hyperactivity disorder: a guide for pediatric neurologists.
    Wigal SB; Chae S; Patel A; Steinberg-Epstein R
    Semin Pediatr Neurol; 2010 Dec; 17(4):230-6. PubMed ID: 21183129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concomitant use of atomoxetine and OROS-methylphenidate in a 10-year-old child suffering from attention-deficit/hyperactivity disorder with comorbid bipolar disorder and Tourette syndrome.
    Jaworowski S; Benarroch F; Gross-Tsur V
    J Child Adolesc Psychopharmacol; 2006 Jun; 16(3):365-70. PubMed ID: 16768644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current and Investigational Medication Delivery Systems for Treating Attention-Deficit/Hyperactivity Disorder.
    Jain R; Katic A
    Prim Care Companion CNS Disord; 2016 Aug; 18(4):. PubMed ID: 27828696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of Attention-Deficit/Hyperactivity Disorder in Adolescents: A Systematic Review.
    Chan E; Fogler JM; Hammerness PG
    JAMA; 2016 May; 315(18):1997-2008. PubMed ID: 27163988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term outcomes with medications for attention-deficit hyperactivity disorder: current status of knowledge.
    Huang YS; Tsai MH
    CNS Drugs; 2011 Jul; 25(7):539-54. PubMed ID: 21699268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Practical, Evidence-informed Approach to Managing Stimulant-Refractory Attention Deficit Hyperactivity Disorder (ADHD).
    Cortese S; Newcorn JH; Coghill D
    CNS Drugs; 2021 Oct; 35(10):1035-1051. PubMed ID: 34403134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacotherapy for child and adolescent attention-deficit hyperactivity disorder.
    Kaplan G; Newcorn JH
    Pediatr Clin North Am; 2011 Feb; 58(1):99-120, xi. PubMed ID: 21281851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence-based pharmacotherapy for attention-deficit hyperactivity disorder.
    Biederman J; Spencer T; Wilens T
    Int J Neuropsychopharmacol; 2004 Mar; 7(1):77-97. PubMed ID: 14733627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating Matching-Adjusted Indirect Comparisons in Practice: A Case Study of Patients with Attention-Deficit/Hyperactivity Disorder.
    Shafrin J; Shrestha A; Chandra A; Erder MH; Sikirica V
    Health Econ; 2017 Nov; 26(11):1459-1466. PubMed ID: 27620206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cessation of attention deficit hyperactivity disorder drugs in the young (CADDY)--a pharmacoepidemiological and qualitative study.
    Wong IC; Asherson P; Bilbow A; Clifford S; Coghill D; DeSoysa R; Hollis C; McCarthy S; Murray M; Planner C; Potts L; Sayal K; Taylor E
    Health Technol Assess; 2009 Oct; 13(50):iii-iv, ix-xi, 1-120. PubMed ID: 19883527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of extended-release guanfacine hydrochloride in children and adolescents with attention-deficit/hyperactivity disorder: a randomized, controlled, phase III trial.
    Hervas A; Huss M; Johnson M; McNicholas F; van Stralen J; Sreckovic S; Lyne A; Bloomfield R; Sikirica V; Robertson B
    Eur Neuropsychopharmacol; 2014 Dec; 24(12):1861-72. PubMed ID: 25453486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drugs for ADHD.
    Med Lett Drugs Ther; 2020 Jan; 62(1590):9-15. PubMed ID: 31999670
    [No Abstract]   [Full Text] [Related]  

  • 15. The use of stimulants and atomoxetine in adults with comorbid ADHD and bipolar disorder.
    Perugi G; Vannucchi G
    Expert Opin Pharmacother; 2015; 16(14):2193-204. PubMed ID: 26364896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-Term Pharmacotherapy of Adults With Attention Deficit Hyperactivity Disorder: A Literature Review and Clinical Study.
    Fredriksen M; Peleikis DE
    Basic Clin Pharmacol Toxicol; 2016 Jan; 118(1):23-31. PubMed ID: 26404187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toward quality care in ADHD: defining the goals of treatment.
    Rostain A; Jensen PS; Connor DF; Miesle LM; Faraone SV
    J Atten Disord; 2015 Feb; 19(2):99-117. PubMed ID: 23422237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonstimulant Treatments for ADHD.
    Newcorn JH; Krone B; Dittmann RW
    Child Adolesc Psychiatr Clin N Am; 2022 Jul; 31(3):417-435. PubMed ID: 35697393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of FDA advisories on the pharmacologic treatment of ADHD, 2004-2008.
    Kornfield R; Watson S; Higashi AS; Conti RM; Dusetzina SB; Garfield CF; Dorsey ER; Huskamp HA; Alexander GC
    Psychiatr Serv; 2013 Apr; 64(4):339-46. PubMed ID: 23318985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of alpha2-adrenergic agonists in attention-deficit/hyperactivity disorder.
    Sallee FR
    Postgrad Med; 2010 Sep; 122(5):78-87. PubMed ID: 20861591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.